These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18791716)

  • 1. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
    Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
    Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
    Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
    Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
    Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
    Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
    Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
    J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
    Toka FN; Nfon CK; Dawson H; Golde WT
    Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
    Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
    Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
    Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
    J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
    Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
    J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
    Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
    J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
    Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
    Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.
    Wysocka M; Dawany N; Benoit B; Kossenkov AV; Troxel AB; Gelfand JM; Sell MK; Showe LC; Rook AH
    Leuk Lymphoma; 2011 Oct; 52(10):1970-9. PubMed ID: 21942329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
    Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
    Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
    Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
    Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
    Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
    J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.